OIG Report Highlights Difficulty In Measuring “Widely Available Market Price” For Drugs
Executive Summary
Limitations and irregularities in sales data prevent an accurate comparison of average sales price and widely available market price for Medicare Part B drugs, a differential that can be the basis for modifying reimbursement.